机构:[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院[2]Jiangsu Simcere Diagnost Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Nanjing Simcere Med Lab Sci Co Ltd, Dept Med, Nanjing, Peoples R China
第一作者机构:[1]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China[2]Jiangsu Simcere Diagnost Co Ltd, State Key Lab Translat Med & Innovat Drug Dev, Nanjing Simcere Med Lab Sci Co Ltd, Dept Med, Nanjing, Peoples R China
推荐引用方式(GB/T 7714):
Wang Hongyan,Zhao Xiaopeng,He Xu,et al.PIK3CA-TP53 co-mutation as a biomarker of overall survival in malignant tumor.[J].JOURNAL OF CLINICAL ONCOLOGY.2021,39(15):doi:10.1200/JCO.2021.39.15_suppl.e15001.
APA:
Wang, Hongyan,Zhao, Xiaopeng,He, Xu,Wang, Miao,Zhang, Haoran...&Duan, Qianqian.(2021).PIK3CA-TP53 co-mutation as a biomarker of overall survival in malignant tumor..JOURNAL OF CLINICAL ONCOLOGY,39,(15)
MLA:
Wang, Hongyan,et al."PIK3CA-TP53 co-mutation as a biomarker of overall survival in malignant tumor.".JOURNAL OF CLINICAL ONCOLOGY 39..15(2021)